Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor

Author： Kwasny W.  

Publisher： Springer Publishing Company

ISSN： 0167-6806

Source： Breast Cancer Research and Treatment, Vol.63, Iss.3, 2000-10, pp. : 235-241

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer

By Mori K.   Hirose T.   Machida S.   Yokoyama K.   Tominaga K.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 503-505

Elsevier

Access to resources Recommend Favorite

The Feasibility of Using Glycosylated Recombinant Human Granulocyte Colony-stimulating Factor (G-CSF) to Increase the Planned Dose Intensity of Doxorubicin, Cyclophosphamide and Etoposide (ACE) in the Treatment of Small Cell Lung Cancer

By Thatcher N.   Anderson H.   Bleehen N.M.   Girling D.J.   Lallemand G.   Machin D.   Stephens R.J.  

European Journal of Cancer, Vol. 31, Iss. 2, 1995-01 ,pp. : 152-156

Elsevier

Access to resources Recommend Favorite

A Randomised Study Comparing Granulocyte-colony Stimulating Factor (G-CSF) with G-CSF Plus Thymostimulin in the Treatment of Haematological Toxicity in Patients with Advanced Breast Cancer after High Dose Mitoxantrone Therapy

By Sanchiz F.   Milla A.  

European Journal of Cancer, Vol. 32, Iss. 1, 1996-01 ,pp. : 52-56

Elsevier

Access to resources Recommend Favorite

Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor

By Stoger H.   Samonigg H.   Krainer M.   Ploszczynski M.   Nirnberger G.   Maca S.   Hehenwarter W.   Wirth M.   Schuller J.   Vavra N.   Scheithauer W.   Kornek G.   Stierer M.   Zielinski C.C.  

European Journal of Cancer, Vol. 34, Iss. 4, 1998-03 ,pp. : 482-488

Elsevier

Access to resources Recommend Favorite

An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer

By Bonnefoi H.  

Breast Cancer Research and Treatment, Vol. 70, Iss. 1, 2001-11 ,pp. : 55-63

Springer Publishing Company

Access to resources Recommend Favorite